Literature DB >> 21370475

Target-selective drug delivery through liposomes labeled with oligobranched neurotensin peptides.

Chiara Falciani1, Antonella Accardo, Jlenia Brunetti, Diego Tesauro, Barbara Lelli, Alessandro Pini, Luisa Bracci, Giancarlo Morelli.   

Abstract

The structure and the in vitro behavior of liposomes filled with the cytotoxic drug doxorubicin (Doxo) and functionalized on the external surface with a branched moiety containing four copies of the 8-13 neurotensin (NT) peptide is reported. The new functionalized liposomes, DOPC-NT₄Lys(C₁₈)₂, are obtained by co-aggregation of the DOPC phospholipid with a new synthetic amphiphilic molecule, NT₄ Lys(C₁₈)₂, which contains a lysine scaffold derivatized with a lipophilic moiety and a tetrabranched hydrophilic peptide, NT8-13, a neurotensin peptide fragment well known for its ability to mimic the neurotensin peptide in receptor binding ability. Dynamic light scattering measurements indicate a value for the hydrodynamic radius (RH) of 88.3±4.4 nm. The selective internalization and cytotoxicity of DOPC-NT₄ Lys(C₁₈)₂ liposomes containing Doxo, as compared to pure DOPC liposomes, were tested in HT29 human colon adenocarcinoma and TE671 human rhabdomyosarcoma cells, both of which express neurotensin receptors. Peptide-functionalized liposomes show a clear advantage in comparison to pure DOPC liposomes with regard to drug internalization in both HT29 and TE671 tumor cells: FACS analysis indicates an increase in fluorescence signal of the NT₄-liposomes, compared to the DOPC pure analogues, in both cell lines; cytotoxicity of DOPC-NT₄ Lys(C₁₈)₂-Doxo liposomes is increased four-fold with respect to DOPC-Doxo liposomes in both HT29 and TE671 cell lines. These effects could to be ascribed to the higher rate of internalization for DOPC-NT₄ Lys(C₁₈)₂-Doxo liposomes, due to stronger binding driven by a lower dissociation constant of the NT₄-liposomes that bind the membrane onto a specific protein, in contrast to DOPC liposomes, which approach the plasma membrane unselectively.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21370475     DOI: 10.1002/cmdc.201000463

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  17 in total

1.  A simple synthesis of a targeted drug delivery system with enhanced cytotoxicity.

Authors:  Sanjib Bhattacharyya; Maria Gonzalez; J David Robertson; Resham Bhattacharya; Priyabrata Mukherjee
Journal:  Chem Commun (Camb)       Date:  2011-06-30       Impact factor: 6.222

Review 2.  Liposomal Nanostructures for Drug Delivery in Gastrointestinal Cancers.

Authors:  Manisit Das; Leaf Huang
Journal:  J Pharmacol Exp Ther       Date:  2018-12-12       Impact factor: 4.030

3.  Optimization of a cyclic peptide inhibitor of Ser/Thr phosphatase PPM1D (Wip1).

Authors:  Ryo Hayashi; Kan Tanoue; Stewart R Durell; Deb K Chatterjee; Lisa M Miller Jenkins; Daniel H Appella; Ettore Appella
Journal:  Biochemistry       Date:  2011-05-09       Impact factor: 3.162

4.  Peptide-mediated liposomal Doxorubicin enhances drug delivery efficiency and therapeutic efficacy in animal models.

Authors:  De-Kuan Chang; Pi-Chun Li; Ruei-Min Lu; Wann-Neng Jane; Han-Chung Wu
Journal:  PLoS One       Date:  2013-12-27       Impact factor: 3.240

5.  Tumor-selective peptide-carrier delivery of Paclitaxel increases in vivo activity of the drug.

Authors:  Jlenia Brunetti; Serena Pillozzi; Chiara Falciani; Lorenzo Depau; Eleonora Tenori; Silvia Scali; Luisa Lozzi; Alessandro Pini; Annarosa Arcangeli; Stefano Menichetti; Luisa Bracci
Journal:  Sci Rep       Date:  2015-12-02       Impact factor: 4.379

6.  Influence of PEGylation and RGD loading on the targeting properties of radiolabeled liposomal nanoparticles.

Authors:  Christine Rangger; Anna Helbok; Elisabeth von Guggenberg; Jane Sosabowski; Thorsten Radolf; Ruth Prassl; Fritz Andreae; Gudrun C Thurner; Roland Haubner; Clemens Decristoforo
Journal:  Int J Nanomedicine       Date:  2012-11-27

Review 7.  Application of liposomes in drug development--focus on gastroenterological targets.

Authors:  Jian-Xin Zhang; Kun Wang; Zheng-Fa Mao; Xin Fan; De-Li Jiang; Min Chen; Lei Cui; Kang Sun; Sheng-Chun Dang
Journal:  Int J Nanomedicine       Date:  2013-04-08

Review 8.  Receptor binding peptides for target-selective delivery of nanoparticles encapsulated drugs.

Authors:  Antonella Accardo; Luigi Aloj; Michela Aurilio; Giancarlo Morelli; Diego Tesauro
Journal:  Int J Nanomedicine       Date:  2014-03-27

9.  Insights into the role of sulfated glycans in cancer cell adhesion and migration through use of branched peptide probe.

Authors:  Jlenia Brunetti; Lorenzo Depau; Chiara Falciani; Mariangela Gentile; Elisabetta Mandarini; Giulia Riolo; Pietro Lupetti; Alessandro Pini; Luisa Bracci
Journal:  Sci Rep       Date:  2016-06-03       Impact factor: 4.379

10.  Coupling to a cancer-selective heparan-sulfate-targeted branched peptide can by-pass breast cancer cell resistance to methotrexate.

Authors:  Lorenzo Depau; Jlenia Brunetti; Chiara Falciani; Silvia Scali; Giulia Riolo; Elisabetta Mandarini; Alessandro Pini; Luisa Bracci
Journal:  Oncotarget       Date:  2017-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.